logo
Trust on hold: Companies slam brakes on trade credit amid soaring bad debts

Trust on hold: Companies slam brakes on trade credit amid soaring bad debts

Photo: Depositphotos/ sitthipong.pak.gmail.com (for illustration purposes only)
SINGAPORE: More Singaporean businesses are facing financial strain as unpaid invoices increase, now averaging 6% across industries. This trend points to worsening financial pressure among corporate clients.
According to the recent B2B Payment Practices Trends in Singapore 2025 report by global credit insurer Atradius, featured in the latest SBR report, these unpaid bills, often called 'bad debts,' are steadily impacting profit margins and revealing weaknesses in various sectors.
The sectors on construction and agri-food were hit the hardest, with each industry reporting an average of 7% in bad credits. The energy and fuel sector performs slightly better, averaging a significant 5%.
In response, companies are being more cautious. About half are reducing the trade credit they offer to corporate clients. Others are tightening payment terms to protect themselves from increasing credit risk. Even those offering more credit are becoming more stringent, with constricted deadlines becoming the norm.
At present, more than half, or 54%, of B2B businesses in Singapore are accomplished on credit, with an average payment period of 46 days. Nevertheless, 35% of these accounts end up unsettled, principally because of clients' cash flow problems or unsolved disagreements.
The energy and fuel segment is at the forefront in credit-based transactions at 58%, followed closely by the construction sector at 55%. The agri-food industry, while using the least credit, at 47%, has a very high rate of unpaid accounts, 43% of these accounts are unsettled. This compares to 37% in construction and 30% in energy and fuel.
Despite the increase in bad debt, most businesses, 70%, expect insolvency rates among clients to stay stable in the near future. Nevertheless, companies are not taking risks. Many are stepping up debt collection efforts and reviewing payment policies to safeguard their cash flow.
Around 62% of firms are working to reduce their Days Sales Outstanding (DSO) to improve cash flow. However, slow inventory turnover might limit how much cash can be released.
Adding to the burden, 70% of dealings report being overstretched by contractors and providers who demand quicker payments, further constricting the financial congestion across the supply chain. See also Trump's tariff policy does not represent all of America
As the burden of attaining financial flexibility surges, the corporate world of Singapore is on its way to framing a more vigilant and meticulous credit-aware future. document.addEventListener("DOMContentLoaded", () => { const trigger = document.getElementById("ads-trigger"); if ('IntersectionObserver' in window && trigger) { const observer = new IntersectionObserver((entries, observer) => { entries.forEach(entry => { if (entry.isIntersecting) { lazyLoader(); // You should define lazyLoader() elsewhere or inline here observer.unobserve(entry.target); // Run once } }); }, { rootMargin: '800px', threshold: 0.1 }); observer.observe(trigger); } else { // Fallback setTimeout(lazyLoader, 3000); } });
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs

Straits Times

timean hour ago

  • Straits Times

Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs

Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.

Getting residents to buy into VERS could be a challenge: Real estate analysts
Getting residents to buy into VERS could be a challenge: Real estate analysts

CNA

time5 hours ago

  • CNA

Getting residents to buy into VERS could be a challenge: Real estate analysts

Real estate analysts said it could be challenging to get residents to buy into the Voluntary Early Redevelopment Scheme, or VERS. Some said the government could make it more attractive by offering incentives, such as priority in purchasing a new flat. Residents of older estates have voiced concerns over compensation and affordability of flats in the area. As home owners have diverse needs, experts said sensitivity and prudence is required if VERS is to adequately address the impact of lease decay.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store